Quality of Life Analysis of Arimidex Treatment in Postmenopausal Patients With Breast Cancer (RADAR II E)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
Child, Adult, Older Adult
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Postmenopausal, hormonreceptor positive patients with early breast cancer treated with Arimidex (in accordance with the local SmPC).
Provision of informed consent
Postmenopausal, hormon receptor positive patients with early breast cancer treated with Arimidex
Investigators are requested to recruit patients only with at least 1 month prior Arimidex treatment.